During Wednesday’s Current trade, Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI), gain 8.57% to $48.80.
Intra-Cellular Therapies, Inc. (ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, declared recently that it is assuming sponsorship of the Investigational New Drug Application (IND) for studies related to ITI-214. ITI-214 is a novel, potent phosphodiesterase type 1 (PDE1) inhibitor. Multiple human clinical Phase 1 studies have been accomplished. In these studies, ITI-214 demonstrated a favorable safety profile and was generally well-tolerated across a broad range of doses both in healthy volunteers and in patients with schizophrenia with a pharmacokinetic profile that supports once daily dosing.
Under a license agreement, Takeda conducted four Phase 1 studies. A single rising dose study was conducted in the US in healthy male and female, Japanese and non-Japanese volunteers. In a second US study ITI-214 was administered once daily over 14 days to healthy volunteers and patients with stable schizophrenia. In a third study, conducted in Japan, ITI-214 was administered for 7 days at multiple rising oral doses in both male and female healthy volunteers. A fourth study contrast the relative bioavailability of oral formulations of ITI-214 used in all previous studies to an immediate-release tablet, either with or without food in healthy volunteers.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system (CNS). Its lead drug candidate is ITI-007, which is in phase III clinical development for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder, depression, and other neuropsychiatric and neurological disorders.
Corrections Corp Of America (NYSE:CXW), during its Wednesday’s current trading session decreased -0.32% to $30.99.
CCA (NYSE: CXW), America’s largest owner of partnership correctional and detention facilities, declared recently that its Board of Directors declared a quarterly dividend of $0.54 per share to be paid on October 15, 2015 to shareholders of record as of the close of business on October 2, 2015.
Corrections Corporation of America, together with its auxiliaries, owns and operates privatized correctional and detention facilities in the United States. It owns, operates, and manages prisons and other correctional facilities; and provides inmate residential and prisoner transportation services for governmental agencies. The company also offers various rehabilitation and educational programs, counting basic education, religious services, life skills and employment training, and substance abuse treatment, in addition to food services, work and recreational programs, and healthcare services, such as medical, dental, and mental health services. In addition, it leases its facilities to third-party operators .
Finally, Raptor Pharmaceutical Corp.(NASDAQ:RPTP), gained 3.48%, to $6.68.
Raptor Pharmaceutical Corp. (RPTP) declared that it will take part in the following investor conference:
Julie Anne Smith, President and Chief Executive Officer, will take part in the Leerink Partners 4th Annual Rare Disease Roundtable being held Wednesday, September 30, 2015 at Le Parker Meridien Hotel in New York. The company is planned to present at 10:40 a.m. EDT (7:40 a.m. PDT).
Raptor Pharmaceutical Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
